EPH58 Adverse Events Associated with Sodium Glucose Co-Transporter-2 Inhibitors: A Pharmacoepidemiologic Analysis Using FAERS Database 2012-2022

Sodium Glucose Co-Transporter-2 (SGLT2) inhibitors canagliflozin, dapagliflozin, and empagliflozin are commonly used for type 2 diabetes mellitus treatment. The FDA warns of serious adverse events (AEs) related to the use of SGLT2 inhibitors, such as limb amputations, kidney injury and ketoacidosis

Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: M. Gari, M. Alrasheed, J.J. Guo Source Type: research